Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY ORDERS 20,000 THYMOSIN ALPHA-1 PATCHES FOR COMMERCIAL LAUNCH

The Precision Peptide Company Inc. has placed an order for 20,000 units of its Thymosin Alpha-1 (TA1) transdermal patch. The order is intended to support the patch's planned commercial release and represents the company's initial commercial production run of the product. Each patch is formulated to deliver two milligrams (mg) of TA1.

The order follows the company's Sept. 8, 2026, news release, "The Precision Peptide Company Advances Thymosin Alpha-1 Patch into Formal U.S. Testing," regarding the development of its Thymosin Alpha-1 transdermal patch. The order is for patches formulated with a two mg dose of Thymosin Alpha-1.

TA1 is a naturally occurring peptide present in the thymus that has been studied for its immune-modulating properties. In the clinical studies included in a 2025 systematic review and meta-analysis, TA1 was administered by subcutaneous injection. That study did not evaluate the company's patch, which remains under development and testing. The patch is designed as a wearable wellness product that applies directly to the skin, with no injections, no reconstitution and no user-administered dose measurement.

The patch is the second product to advance through the company's transdermal development pathway into commercial production, following the BPC-157 patch. Based on its review of currently available products, the company believes it could be among the first to market with a TA1 transdermal patch.

The full production run will be manufactured and tested in the United States through the company's United States-based product infrastructure. The company expects to receive the finished production run in January, 2027, with an initial commercial release to follow, subject to receipt and final quality review.

Pratap Sandhu, chief executive officer of Precision Peptide Company, commented:

"We have placed an order for 20,000 TA1 transdermal patches. This is the second time we have advanced a peptide patch from testing into a commercial production order and it confirms our development model is repeatable. The needle has been the biggest barrier to Thymosin Alpha-1 and this order moves a needle-free format toward market. Our focus now is completing production and preparing for launch."

About The Precision Peptide Company Inc.

Precision Peptide Company is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.